View Full Version : Argos Therapeutics Initiates Dosing Of Patients In Phase 1 Clinical Trial Of Monoclon

12-08-2010, 08:11 AM
Argos Therapeutics announced that it has initiated dosing of patients in a Phase 1 clinical trial of its monoclonal antibody-based therapy, AGS-009, for the treatment of systemic lupus erythematosus (SLE). AGS-009 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with the ability to bind and neutralize human interferon alpha (IFN-alpha)...

More... (http://mnt.to/f/3NLf)